# EDGAR Filing Document

**Accession Number:** 0002042266
**File Stem:** 0001193125-25-316569
**Filing Date:** 2025-12
**Character Count:** 9066
**Document Hash:** 9bbf4c9edbb1a9a32fa398d23d1e70a1
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-316569.hdr.sgml**: 20251211

**ACCESSION NUMBER**: 0001193125-25-316569

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251211

**DATE AS OF CHANGE**: 20251211

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Opus Genetics, Inc.
- **CENTRAL INDEX KEY:** 0001228627
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 113516358
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-79996
- **FILM NUMBER:** 251566338

**BUSINESS ADDRESS:**
- **STREET 1:** 8 DAVIS DRIVE
- **STREET 2:** SUITE 220
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27713
- **BUSINESS PHONE:** 248-681-9815

**MAIL ADDRESS:**
- **STREET 1:** 8 DAVIS DRIVE
- **STREET 2:** SUITE 220
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27713

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Ocuphire Pharma, Inc.
- **DATE OF NAME CHANGE:** 20201109

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** REXAHN PHARMACEUTICALS, INC.
- **DATE OF NAME CHANGE:** 20050516

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** CORPORATE ROAD SHOW DOT COM INC
- **DATE OF NAME CHANGE:** 20030423
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Foundation Fighting Blindness Retinal Degeneration Fund
- **CENTRAL INDEX KEY:** 0002042266

**ORGANIZATION NAME:**
- **EIN:** 450524687
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 223 S. WEST STREET, SUITE 900
- **CITY:** RALEIGH
- **STATE:** NC
- **ZIP:** 27603
- **BUSINESS PHONE:** 800-683-5555

**MAIL ADDRESS:**
- **STREET 1:** 223 S. WEST STREET, SUITE 900
- **CITY:** RALEIGH
- **STATE:** NC
- **ZIP:** 27603

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 2)**

**Opus Genetics, Inc.**

*(Name of Issuer)*

**Common Stock, $0.0001 par value per share**

*(Title of Class of Securities)*

**67577R102**

*(CUSIP Number)*

**Russell Kelley, Managing Dir.**<br>Foundation Fighting Blindness RD Fund<br>223 S. West Street, Suite 900<br>Raleigh NC 27603<br>(919) 610-2064

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**12/09/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **67577R102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Foundation Fighting Blindness Retinal Degeneration Fund** | Name of reporting person<br>**Foundation Fighting Blindness Retinal Degeneration Fund** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**DELAWARE** | Citizenship or place of organization<br>**DELAWARE** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5492171.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5492171.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5492171.00** | Aggregate amount beneficially owned by each reporting person<br>**5492171.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.0%** | Percent of class represented by amount in Row (11)<br>**8.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** Percent of class represented in Row (11) is based on 68,964,208 shares of common stock, $0.0001 par value per share (the "Common Stock") of Opus Genetics, Inc., a Delaware corporation (the "Issuer") outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on November 12, 2025.

| **CUSIP No.** | **67577R102** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Foundation Fighting Blindness, Inc.** | Name of reporting person<br>**Foundation Fighting Blindness, Inc.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[ ] (a)<br>[x] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**MARYLAND** | Citizenship or place of organization<br>**MARYLAND** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**5492171.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**5492171.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**5492171.00** | Aggregate amount beneficially owned by each reporting person<br>**5492171.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**8.0%** | Percent of class represented by amount in Row (11)<br>**8.0%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** Percent of class represented in Row (11) is based on 68,964,208 shares of the Issuer's Common Stock outstanding as of November 10, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on November 12, 2025.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, $0.0001 par value per share

**(b) Name of Issuer:**
Opus Genetics, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
8 Davis Drive, Suite 220, Suite 200, Durham, NC, 27713

This Amendment No. 2 on Schedule 13D amends the statement on Schedule 13D, dated October 29, 2024, which was amended on Schedule 13D/A dated March 6, 2025, which relates to the Common Stock of the Issuer, filed by the Reporting Persons. This Amendment No. 2 on Schedule 13D is being filed to show the change in percentage of beneficial ownership held by the Reporting Persons as a result of selling shares of the Issuer's Common Stock on December 9, 2025.

**Item 5. Interest in Securities of the Issuer**

**(a)**
5492171 - 8%

**(b)**
5492171

**(c)**
Reference is made to the Form 4 filed by the Reporting Persons on December 11, 2025 with the SEC pursuant to Section 16 of the Act and is available on the SEC's website at www.sec.gov.  The information reported in the filings are expressly incorporated herein.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Foundation Fighting Blindness Retinal Degeneration Fund

**Signature:** /s/ Russell Kelley

**Name/Title:** Russell Kelley, Managing Director

**Date:** 12/11/2025

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Foundation Fighting Blindness, Inc.

**Signature:** /s/ Jason Menzo

**Name/Title:** Jason Menzo, Chief Executive Officer

**Date:** 12/11/2025